Dexcom Inc is a leading company specializing in continuous glucose monitoring systems for individuals with diabetes
Their innovative technology enables users to track glucose levels in real time through a small sensor placed under the skin, eliminating the need for traditional fingerstick testing. The company's products empower patients and healthcare providers to make informed decisions regarding diabetes management, enhancing the quality of life for those living with the condition. By integrating advanced software and mobile applications, Dexcom's systems deliver essential insights and alerts, contributing to better health outcomes for users.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom (NASDAQDXCM).
Medical technology company iRhythm Technologies (NASDAQIRTC)
will be announcing earnings results tomorrow afternoon. Here’s what investors should know.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session.
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts highlighted long-term growth potential.
Medical device company DexCom (NASDAQDXCM) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 7.6% year on year to $1.11 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.45 per share was 9.9% below analysts’ consensus estimates.
Based on a technical and fundamental analysis of NASDAQ:DXCM we can say: DEXCOM INC (NASDAQDXCM)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
